Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TSD to aid Eisai's Japanese development of denileukin

This article was originally published in Scrip

Executive Summary

TSD Japan, a private drug development venture, has been granted the exclusive right to co-develop Eisai's cancer product denileukin diftitox for the Japanese market. Eisai has retained the exclusive right to market the fusion protein in what is its home territory.

You may also be interested in...



Japan 2010s In Review: Specialize, Focus, Innovate

Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.

Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate

BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005201

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel